Intomics

Intomics is a Denmark-based company specializing in advanced biomedical research services aimed at enhancing drug discovery and development through innovative solutions leveraging artificial intelligence and machine learning. Intomics, founded by Niclas Hansen, operates in the biomedical research domain, focusing on drug discovery and development. The company was acquired by ZS Associates in May 2022, although financial terms of the deal were not disclosed. The headquarters are located in Denmark.

The total amount raised by Intomics is USD 3. 00 mn through its latest funding round backed by The Danish National Advanced Technology Foundation. Intomics provides advanced biomedical research services, specializing in drug discovery and development. The company's integrated solutions utilize artificial intelligence and machine learning to assist clients in understanding disease biology, optimizing patient stratification, and identifying novel biomarkers and therapeutic targets.

Intomics serves a diverse clientele in the life sciences sector, including major pharmaceutical and biotech firms, healthcare providers, and research organizations across North America, Europe, and Asia. Intomics generates revenue through subscription models and project-based partnerships with life sciences organizations, focusing on B2B transactions. Their advanced analytics and drug development services are provided under tailored agreements, often involving performance-based pricing structures aimed at specific outcomes related to research endeavors. In the most recent fiscal year, the company reported an EBITDA of USD -2,109,122.

50. Intomics aims to expand its offerings and reach by designing new products tailored for the life sciences market. The company is targeting expansion into additional geographic regions, though specific markets have not been disclosed. The funding received in May 2022 will support these initiatives, allowing Intomics to further enhance its research capabilities and product offerings.